Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492322 · ClinicalTrials.gov registry record
SPECT Imaging of DAT Genotype
A clinical trial, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- 14
- Enrollment target
NCT01492322: Clinical Trial study, sponsored by University of Pennsylvania.
NCT01492322 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492322 was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
A polymorphism in the dopamine transporter (DAT) may determine how much dopamine is available at the synapse and this may affect the underlying reasons for relapse in smokers. This research will use Single-photon emission computed tomography SPECT and the DAT-specific ligand, TRODAT (Dopamine Transporter Density by \[99mTc\]), to examine the availability of DAT in smokers grouped by genotype in the sated (just having smoked) and withdrawal (4 hours without smoking) conditions.
Primary Outcome
To determine differences in TRODAT binding to the DAT between smokers who are sated and those who are in withdrawal
Interventions
- RADIATION TRODAT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-10 |
Why NCT01492322 stopped before completion
NCT01492322 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which TRODAT is the first listed.
NCT01492322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01492322 about?
NCT01492322 is a clinical study titled "SPECT Imaging of DAT Genotype". A polymorphism in the dopamine transporter (DAT) may determine how much dopamine is available at the synapse and this may affect the underlying reasons for relapse in smokers. This research will use Single-photon emission computed tomography SPECT and the DAT-specific ligand, TRODAT (Dopamine Transp...
What is the current status of trial NCT01492322?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2011-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01492322?
The interventions under investigation include: TRODAT (RADIATION).
Who is sponsoring clinical trial NCT01492322?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia